Objective: To investigate the clinical efficacy and safety of sodium valproate combined with escitalopram oxalate in the treatment of idiopathic epilepsy combined with depression. Methods: 68 cases of idiopathic epilepsy combined with depression in our hospital were randomly divided into two groups(34 cases in each group), the control group was treated with sodium valproate combined with citalopram, the observation group was given sodium valproate combined with escitalopram oxalate. The two groups of clinical curative effect, scores of Hamilton depression scale(HAMD) and Hamilton anxiety scale(HAMA) pre-treatment, treatment for one month, treatment for two months and six months were compared, and the lipid indicators and thyroid function indicators of patients before and after treatment were monitored. Results: The complete control rate and the total effective rate of the observation group were 58.82% and 97.06%, respectively, which were significantly higher than those of the control group(41.18% and 82.35%)(P<0.05);The HAMD scores and HAMA scores of the two groups after treatment were significantly lower than those before treatment, and which in the observation group were lower than those in the control group(P<0.05);The levels of TG, TC and LDL-C in both groups after treatment were significantly higher than those before treatment(P<0.05), and there was no significant difference between the two groups(P>0.05);The TSH levels of the two groups after treatment were significantly higher than those before treatment(P<0.05), FT4 level was significantly lower than before treatment(P<0.05), but there was no significant difference between the two groups(P>0.05).Conclusion: Sodium valproate combined with escitalopram oxalate in the treatment of idiopathic epilepsy combined with depression is effective and which can significantly improve anxiety and depression in patients, but long-term use of sodium valproate will interfere with lipid metabolism, affect thyroid hormone levels, therefore, the blood lipid monitoring of patients in the treatment should be strengthened. |
[1] 李继,王建军,李烨,等.草酸艾司西酞普兰对脑卒中后抑郁、认知及神经功能的影响[J].河北医科大学学报,2017,38(5):589-592.
[2] LI M,HENG X,TAO R,et al.A genetic epidemiological survey of idiopathic epilepsy in the Chinese Han population[J].Epilepsy Research,2012,98(2/3):199-205.
[3] BONINI F,EGEO G,FATTOUCH J,et al.Natural evolution from idiopathic photosensitive occipital lobe epilepsy to idiopathic generalized epilepsy in an untreated young patient[J].Brain & Development,2014,36(4):346-350.
[4] 韦迪岱,陈晋,郑文明,等.拉莫三嗪与丙戊酸钠对改善颅脑损伤后晚期癫痫疗效的比较[J].重庆医学,2015,33(22):3125-3126.
[5] 夏杰,郑铮,张其梅,等.奥卡西平和丙戊酸钠对癫痫患者血浆同型半胱氨酸和不对称二甲基精氨酸水平的影响[J].重庆医学,2015,21(6):783-784.
[6] 林晓静,杨建波,邹全,等.丙戊酸钠片对老年癫痫患者腺苷酶水平的影响[J].中国老年学杂志,2014,33(19):5349-5350.
[7] 白树新,王德斌,李广玉,等.草酸艾司西酞普兰与盐酸帕罗西汀治疗脑卒中后抑郁的临床对照研究[J].河北医药,2013,35(2):230-231.
[8] 郑学宝,王洪飞,吴新君,等.草酸艾司西酞普兰联合奥氮平治疗老年抑郁症的临床疗效及安全性研究[J].中国临床药理学杂志,2015,23(7):495-497.
[9] 林若庭,洪志林,蔡若蔚,等.丙戊酸钠缓释片治疗老年癫痫患者的临床疗效[J].中国老年学杂志,2015,18(3):612-613.
[10] HEATH R P,ANNE T B,GRAEME D J,et al.Sodium valproate use is associated with reduced parietal lobe thickness and brain volume[J].Neurology,2013,80(20):1895-1900.
[11] 张其梅,夏杰,郑铮,等.丙戊酸钠和卡马西平对癫痫患者血同型半胱氨酸、叶酸、维生素B12水平的影响[J].临床神经病学杂志,2012,25(4):291-292.
[12] WEAAELS A M,JIN Y,POLLOCK B G,et al.Adherence to escitalopram treatment in depression:a study of electronically compiled dosing histories in the ‘Depression:the search for phenotypes’ study[J].International Clinical Psychopharmacology,2012,27(6):291-297.
[13] 潘继英,全传升.草酸艾司西酞普兰治疗脑卒中后抑郁的疗效分析[J].神经疾病与精神卫生,2013,13(4):387-388.
[14] HANASH J A,HANSEN B H,HANSEN J F.et al.Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome:results from the DEpression in Patients with Coronary ARtery Disease (DECARD) trial[J].Journal of Cardiovascular Pharmacology,2012,60(4):397-405.
[15] 严峻,高作惠,龚传鹏,等.喹硫平联合丙戊酸钠对首发性精神分裂症伴有冲动与攻击行为患者兴奋躁动的影响[J].东南大学学报(医学版),2015,34(4):567-571.
[16] 周光,李倩.草酸艾司西酞普兰联合丙戊酸钠治疗特发性癫痫合并抑郁的疗效观察[J].医学综述,2016,22(9):1793-1796. |